false
OasisLMS
zh-CN,zh-TW,en,fr,de,hi,ja,ko,pt,es
Login
Catalog
Once-Weekly Insulin: Innovations for Less Interven ...
Once-Weekly Insulin: Innovations for Less Interven ...
Once-Weekly Insulin: Innovations for Less Intervention in Diabetes
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
Dr. Rodolfo Galindo reviewed two once-weekly basal insulins for adults with type 2 diabetes: insulin icodec and efsitora. Their main potential benefit is reducing the burden of daily injections and improving adherence, while providing glucose-lowering effects comparable to daily basal insulins.<br /><br />Across phase 3 trials, both insulins met noninferiority targets for A1C reduction, with no overall increase in hypoglycemia. Their long duration and gradual accumulation mean dosing and titration require care; loading doses may help achieve effective levels sooner. Galindo emphasized following product-label guidance, monitoring patients—especially during initiation or illness—and selecting people with relatively stable glucose needs who want fewer injections. They may be less suitable when frequent dose adjustments are needed.<br /><br />Evidence remains limited for type 1 diabetes, pregnancy, and some other special situations. The Q&A also addressed combining weekly insulin with GLP-1 therapy, use alongside automated insulin delivery, missed or extra doses, hospitalization, and procedures. Galindo advised caution where evidence is lacking and stressed that patients and clinicians need experience with these newer treatments.
Keywords
type 2 diabetes
once-weekly basal insulin
insulin icodec
efsitora
A1C reduction
hypoglycemia
adherence
GLP-1 therapy
×
Please select your language
1
English